Catalog No.
DHH02225
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG1-Kappa
Clonality
Monoclonal
Target
Programmed cell death protein 1, Protein PD-1, hPD-1, PD1, PDCD1, CD279
Concentration
2.42 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q15116
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
AK-105, CAS: 2350298-92-7
Clone ID
Penpulimab
Efficiency and safety of neoadjuvant PD-1 inhibitor (penpulimab) combined with chemotherapy in resectable N1/N2 non-small cell lung cancer: a prospective cohort study., PMID:40503768
Severe immunotherapy-related thrombocytopenia in metastatic bone cancer: a multicenter retrospective case series highlighting early recognition and management., PMID:40496609
Penpulimab in an adolescent patient with pancreatic neuroendocrine carcinoma with liver metastasis: A case report and literature review., PMID:40489810
Penpulimab-kcqx-A Breakthrough in Nasopharyngeal Carcinoma Immunotherapy and the Urgent Need for Global Access., PMID:40415714
Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial., PMID:40349716
Treatment of Retroperitoneal Well-Differentiated Liposarcoma with Combination of Penpulimab and Anlotinib: A Case Report and Literature Review., PMID:40326946
Economic Evaluation of Penpulimab Plus Paclitaxel and Carboplatin Combination Therapy as First-Line Treatment for Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer in China., PMID:40257742
The cost effectiveness of penpulimab with paclitaxel and carboplatin in first-line treatment of metastatic squamous non-small cell lung cancer., PMID:40221588
Cost-effectiveness analysis of penpulimab combined with paclitaxel and carboplatin as first-line treatment for advanced squamous non-small cell lung cancer., PMID:40196373
Cost-effectiveness analysis of penpulimab combined with paclitaxel and carboplatin as a first-line treatment for metastatic squamous non-small cell lung cancer in China., PMID:40032375
Efficacy of the PD-1 inhibitor penpulimab in combination with chemotherapy for advanced lung squamous cell carcinoma: insights from a phase III multicenter study., PMID:39975732
A network comparison on efficacy and safety profiling of PD-1/PD-L1 inhibitors in first-line treatment of advanced non-small cell lung cancer., PMID:39834801
Penpulimab and Anlotinib in PDL1 high-expression pulmonary giant cell carcinoma with cerebral metastases: case report and review., PMID:39763602
Rapid Response to Penpulimab Combined With Anlotinib and Chemotherapy in a Thoracic SMARCA4-UT Without PD-L1 Expression: A Case Report and Review of Literature., PMID:39648153
Efficacy and safety of anlotinib plus penpulimab as second-line treatment for small cell lung cancer: A multicenter, open-label, single-arm phase II trial., PMID:39371104
Fc-Fc interactions and immune inhibitory effects of IgG4: implications for anti-PD-1 immunotherapies., PMID:38925680
Penpulimab, an anti-PD-1 antibody, for heavily pretreated metastatic nasopharyngeal carcinoma: a single-arm phase II study., PMID:38890298
First-line penpulimab (an anti-PD1 antibody) and anlotinib (an angiogenesis inhibitor) with nab-paclitaxel/gemcitabine (PAAG) in metastatic pancreatic cancer: a prospective, multicentre, biomolecular exploratory, phase II trial., PMID:38844468
Comparison of efficacy and safety of PD-1/PD-L1 combination therapy in first-line treatment of advanced NSCLC: an updated systematic review and network meta-analysis., PMID:38625495
Phase 1b/2 study of penpulimab (AK105), an antiprogrammed cell death-1 immunoglobulin G1 antibody, in advanced or metastatic solid tumors (AK105-204)., PMID:38412283
First-line penpulimab combined with paclitaxel and carboplatin for metastatic squamous non-small-cell lung cancer in China (AK105-302): a multicentre, randomised, double-blind, placebo-controlled phase 3 clinical trial., PMID:38309287
Pulmonary blastoma is successfully treated with immunotherapy and targeted therapy., PMID:38280290
Penpulimab combined with anlotinib in patients with R/M HNSCC after failure of platinum-based chemotherapy: a single-arm, multicenter, phase Ⅱ study., PMID:38100934
Case report: the dissociated response and clinical benefit of primary leiomyosarcoma of the bone treated with penpulimab plus lenvatinib after failed multi-line therapy., PMID:38026935
Efficacy and safety of XELOX combined with anlotinib and penpulimab vs XELOX as an adjuvant therapy for ctDNA-positive gastric and gastroesophageal junction adenocarcinoma: a protocol for a randomized, controlled, multicenter phase II clinical trial (EXPLORING study)., PMID:38022553
A case of pancreatic cancer treated with chemotherapy combined with immunotherapy and targeted therapy., PMID:37899397
Penpulimab-induced complete atrioventricular block in a patient with metastatic renal cancer., PMID:37492041
A case report and literature review of immune checkpoint inhibitor-associated pneumonia caused by penpulimab., PMID:37426639
Penpulimab and anlotinib in an elderly patient with recurrent cervical cancer: a case report and literature review., PMID:37340883
Corrigendum: Successful treatment of a patient with multiple-line relapsed extensive-stage small-cell lung cancer receiving penpulimab combined with anlotinib: A case report., PMID:36033531
Penpulimab for Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter, Single-Arm, Pivotal Phase I/II Trial (AK105-201)., PMID:35875118
Penpulimab, an Fc-Engineered IgG1 Anti-PD-1 Antibody, With Improved Efficacy and Low Incidence of Immune-Related Adverse Events., PMID:35833116
Autoimmune hemolytic anemia in patients with relapsed Hodgkin's lymphoma after treatment with penpulimab, a monoclonal antibody against programmed death receptor-1., PMID:35503192
Successful Treatment of a Patient With Multiple-Line Relapsed Extensive-Stage Small-Cell Lung Cancer Receiving Penpulimab Combined With Anlotinib: A Case Report., PMID:35321433
Penpulimab, an anti-PD1 IgG1 antibody in the treatment of advanced or metastatic upper gastrointestinal cancers., PMID:35165764
Antibodies to watch in 2022., PMID:35030985
Penpulimab: First Approval., PMID:34813051
Clinical Activity and Safety of Penpulimab (Anti-PD-1) With Anlotinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: An Open-Label, Multicenter, Phase Ib/II Trial (AK105-203)., PMID:34327136
For research use only. Not for human or drug use.
